Current Neurology and Neuroscience Reports

, Volume 11, Issue 1, pp 15–27

Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New

Authors

  • Simerpreet Bal
    • Departments of Clinical Neurosciences, Calgary Stroke Program, Faculty of MedicineUniversity of Calgary
  • Pawan Ojha
    • Department of NeurologySir J.J. Group of Hospitals
    • Departments of Clinical Neurosciences, Medicine and Community Health Sciences, Faculty of MedicineUniversity of Calgary
Article

DOI: 10.1007/s11910-010-0161-z

Cite this article as:
Bal, S., Ojha, P. & Hill, M.D. Curr Neurol Neurosci Rep (2011) 11: 15. doi:10.1007/s11910-010-0161-z
  • 167 Views

Abstract

Atrial fibrillation is the most common cause of cardioembolic ischemic stroke and has a rising prevalence worldwide. Stroke prevention in this condition is poised to take a substantial leap forward with the evolution of new anticoagulant medications, with superior properties compared to vitamin K antagonists. New, safer and more effective chronic therapy is on the horizon. However, many issues surrounding the management of stroke prevention after an acute stroke and during the course of chronic anticoagulant therapy remain to be resolved.

Keywords

AnticoagulationAtrial fibrillationThrombin inhibitorsStroke

Clinical Trial Acronyms

ACTIVE

Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events

AFASAK

Atrial Fibrillation, Aspirin, and Anticoagulation Study

AFFIRM

Atrial Fibrillation Follow up Investigation of Rhythm Management

AMADEUS

Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients with Atrial Fibrillation

ARISTOTLE

Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation

ATHENA

A Trial with Dronedarone to Prevent Hospitalization or Death in Patients with Atrial Fibrillation

AVERROES

Apixaban Versus Acetylsalicylic Acid to Prevent Strokes

BAATAF

Boston Area Anticoagulation Trial for Atrial Fibrillation

BAFTA

Birmingham Atrial Fibrillation Treatment of the Aged

BOREALIS-AF

Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients with Atrial Fibrillation

ENGAGE AF-TIMI 48

Effective Anticoagulation with Factor xA Next Generation in Atrial Fibrillation

HAEST

Heparin in Acute Embolic Stroke Trial

RACE

Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation

RE-LY

Randomized Evaluation of Long Term Anticoagulant Therapy with Dabigatran Etexilate

ROCKET-AF

Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

SPAF

Stroke Prevention in Atrial Fibrillation

SPINAF

Stroke Prevention in Nonrheumatic Atrial Fibrillation

SPORTIF

Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation

Copyright information

© Springer Science+Business Media, LLC 2010